Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, multicenter study to compare the safety and efficacy of viramidine [taribavirin; Valeant Pharmaceuticals International] to ribavirin in treatment-naive patients with chronic hepatitis C

Trial Profile

Randomized, double-blind, multicenter study to compare the safety and efficacy of viramidine [taribavirin; Valeant Pharmaceuticals International] to ribavirin in treatment-naive patients with chronic hepatitis C

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Taribavirin (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VISER1
  • Sponsors Bausch Health Companies
  • Most Recent Events

    • 21 Jun 2012 Additional lead trial investigator (Ralph T. Doyle) identified as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Primary endpoint 'Sustained virological response rate' has not been met.
    • 25 Mar 2008 The expected completion date for this trial is now 1 Jan 2006.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top